Molecule
Albendazole is an anthelmintic indicated for treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Albendazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Albendazole is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
Source: US FDA prescribing information
Albendazole is a synthetic, antihelminthic drug of the class benzimidazole.
Source: US FDA prescribing information
Patients weighing 60 kg or greater, 400 mg twice daily, less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). Albendazole tablets should be taken with food. Hydatid disease: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. Neurocysticercosis: 8 to 30 days. See additional important information in the Full Prescribing Information.
Source: US FDA prescribing information
Albendazole is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole. Patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole.
Source: US FDA prescribing information
Bone Marrow Suppression: Fatalities have been reported due to bone marrow suppression, monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy. Discontinue albendazole if clinically significant changes in blood counts occur. Embryo-fetal Toxicity: Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate. Discontinue therapy if pregnancy occurs and apprise patient of potential hazard to the fetus. Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy, begin appropriate steroid and anticonvulsant therapy.
Source: US FDA prescribing information
Adverse reactions 1% or greater in hydatid disease: abnormal liver function tests, abdominal pain, nausea/vomiting, reversible alopecia, headache, dizziness/vertigo, fever. Adverse reactions 1% or greater in neurocysticercosis: headache, nausea/vomiting, raised intracranial pressure, meningeal signs.
Source: US FDA prescribing information
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when dexamethasone was coadministered with each dose of albendazole. Praziquantel: In the fed state increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects. Cimetidine: Increased albendazole sulfoxide concentrations in bile and cystic fluid by about 2-fold in hydatid cyst patients. Theophylline: Albendazole induces cytochrome P450 1A in human hepatoma cells, therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Albendazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Albendazole 200 mg tabletOralGeneric name | — | US FDA | Available on request |
| Albenza 200 mg tabletOral | Amneal Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 11 June 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Albendazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Albendazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Albendazole, including Albenza.
Yes. The US FDA first approved Albendazole on 11 June 1996, according to Drugs@FDA.
No listed presentation of Albendazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Albendazole is classified under ATC code P02CA03 (Albendazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.